Related Experiment Videos
Three cases of Wegener's granulomatosis treated with an antimicrobial agent
K Fukuda1, K Yuasa, A Uchizono
1Department of Otolaryngology, Kagoshima (Japan) University School of Medicine.
Abstract:
Sulfamethoxazole-trimethoprim, an antimicrobial agent, was used to treat three cases of cytotoxic agent-resistant Wegener's granulomatosis; one case was refractory to a regimen consisting of azathioprine and prednisolone, and in another two cases the therapy was insufficient to control the disease. By the introduction of sulfamethoxazole-trimethoprim, which has an advantage of fewer side effects compared with the conventional agents, into the regimen, the disease condition was markedly improved in all cases within four months. Sulfamethoxazole-trimethoprim is thus considered as one of the most promising drugs to treat, especially, cytotoxic agent-resistant Wegener's granulomatosis. The possible underlying mechanism of the effect of sulfamethoxazole-trimethoprim is also described.
Insights
Sulfamethoxazole-trimethoprim effectively treated three patients with resistant Wegener's granulomatosis. This antimicrobial agent offered significant improvement with fewer side effects than traditional therapies.
Area of Science:
- Rheumatology
- Infectious Diseases
- Pharmacology
Background:
- Wegener's granulomatosis is a rare autoimmune disease.
- Cytotoxic agents like azathioprine and prednisolone are standard treatments.
- Some cases exhibit resistance or insufficient response to conventional therapies.
Observation:
- Three patients with cytotoxic agent-resistant Wegener's granulomatosis were identified.
- One patient was refractory to azathioprine and prednisolone.
- Two patients had inadequate disease control with existing regimens.
Findings:
- Sulfamethoxazole-trimethoprim was introduced as an alternative treatment.
- All three patients showed marked improvement within four months.
- The drug demonstrated fewer side effects compared to conventional agents.
Implications:
- Sulfamethoxazole-trimethoprim is a promising therapeutic option for resistant Wegener's granulomatosis.
- This agent may be particularly beneficial for patients refractory to cytotoxic drugs.
- Further research into the mechanism of action is warranted.